Opportunities and challenges of pharmacogenomics at scale in a national health service

Add to your list(s) Download to your calendar using vCal

• William Newman (University of Manchester)
• Monday 16 March 2026, 14:30-15:30
• Heart and Lung Research Institute (0.R089).

If you have a question about this talk, please contact Spencer Keene.

SIGN UP HERE: https://www.ticketsource.co.uk/university-of-cambridge/t-xdddagg

Abstract: Over the past decades many genetic variants have been identified that alter individuals’ responses to their medication resulting in ineffective treatment or adverse drug reactions. In England, through the NHS Network of Excellence in Pharmacogenomics, we have developed an implementation science program to adopt pharmacogenomics into routine clinical use. This has focused on the type of genetic test, the way that the data is transferred into an actionable format for the clinician, and determining the clinical outcomes of this intervention.

In this talk, I will discuss the clinical contexts of pharmacogenomics and how a new way of presenting genomic data is required for adoption at scale that is acceptable to both patients and health professionals. I will explore the use of point of care genetic testing and the potential for pre-emptive testing to improve medicines optimisation.

Bio: Bill is a clinician scientist. Professor of Translational Genomic medicine at the University of Manchester and a Consultant in Clinical Genetics at the Manchester Centre for Genomic Medicine. He has a multidisciplinary research program in the implementation of pharmacogenomics in clinical practice and is the lead of the NHS England Network of Excellence in Pharmacogenomics and Medicines Optimisation. He is the immediate past President of the European Society of Human Genetics.

This talk is part of the HDR UK Cambridge Seminar Series series.

This talk is included in these lists:

• HDR UK Cambridge Seminar Series
• Heart and Lung Research Institute (0.R089)
• ndk22's list

Note that ex-directory lists are not shown.